This thread is so damn entertaining I just read through some pages. The BIG Question today is Do Van and Stoney get back on their bicycles? -- Yup we enjoyed a very nice ride on our BCYC's from mid teens to relatively high $20's , got off, left our bike on the side of the road and JMP just picked it up!<----
Bicycle Therapeutics initiated with an Outperform at JMP Securities 05:04 BCYC JMP Securities analyst Reni Benjamin initiated coverage of Bicycle Therapeutics with an Outperform rating and $53 price target. Bicycle toxin conjugates appear to have the specificity and efficacy of antibody drug conjugates but with the pharmacokinetic and property benefits of small molecules, Benjamin tells investors in a research note. With three products in the clinic or already in Phase 2, an early, Bicycle Therapeutics shares "represent a unique investment opportunity" and are attractively priced with 50% potential downside in a bear case and 167% potential upside in a bull case, says the analyst.
Bicycle Therapeutics initiated with an Outperform at JMP Securities 05:04 BCYC JMP Securities analyst Reni Benjamin initiated coverage of Bicycle Therapeutics with an Outperform rating and $53 price target. Bicycle toxin conjugates appear to have the specificity and efficacy of antibody drug conjugates but with the pharmacokinetic and property benefits of small molecules, Benjamin tells investors in a research note. With three products in the clinic or already in Phase 2, an early, Bicycle Therapeutics shares "represent a unique investment opportunity" and are attractively priced with 50% potential downside in a bear case and 167% potential upside in a bull case, says the analyst.
